---
title: 'Funding Daily Summary: What Happened on October 6, 2026'
headline: RougeTx launches with $58 million to advance rare-disease drug
description: Sensible Biotechnologies and WhiteLab Genomics also raised funding for
  mRNA manufacturing and gene-delivery technologies.
url: https://thebench.bio/news/funding/2026-10-06
topic: funding
date: '2026-10-06'
covers:
- '2026-10-06'
date_published: '2026-10-06T12:02:56Z'
date_modified: '2026-10-06T18:49:39Z'
sources: 3
publisher: The Bench (thebench.bio)
---

# Funding Daily Summary: What Happened on October 6, 2026

**RougeTx launches with $58 million to advance rare-disease drug**

Sensible Biotechnologies and WhiteLab Genomics also raised funding for mRNA manufacturing and gene-delivery technologies.

## Today in brief

RougeTx launched with a $58 million Series A to move its hereditary hemorrhagic telangiectasia candidate RTX-001 toward its first human trial. [1] Sensible Biotechnologies raised $47 million, including potential government and European Union support, while WhiteLab Genomics raised $26 million for its gene-delivery platform. [2] [3]

## Also worth knowing

- Sensible plans to expand VECTOR, its mRNA design and screening platform, and build capacity to make clinical-grade material. Up to $20 million of the financing is potential non-dilutive support from Slovakia and the European Union. [2]
- WhiteLab will use its $26 million Series B to test AI-designed gene-delivery components and develop assets it can own and license, including adeno-associated viruses and nonviral methods such as lipid nanoparticles. [3]

## The day in numbers

- **$58 million**: RougeTx's Series A to advance RTX-001 toward its first human trial. [1]
- **$47 million**: Sensible Biotechnologies' financing for its mRNA platform and manufacturing plans. [2]
- **$26 million**: WhiteLab Genomics' Series B to test gene-delivery technologies and develop assets. [3]

## Also published

- [Frontier AI: SME Champions, phase 1](<https://macinchem.org/2026/10/06/frontier-ai-sme-champions-phase-1/>), Mac in Chem

## Sources

1. [RougeTx launches with $58M to tackle rare bleeding disorder](<https://european-biotechnology.com/latest-news/rougetx-launches-with-58m-to-tackle-rare-bleeding-disorder/>), European Biotechnology, 2026-10-06
2. [Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines](<https://www.genengnews.com/topics/drug-discovery/sensible-biotechnologies-raises-47m-to-expand-next-generation-platform-for-mrna-medicines/>), GEN, 2026-10-06
3. [WhiteLab secures $26M to expand AI-designed gene delivery assets](<https://european-biotechnology.com/latest-news/whitelab-secures-26m-to-expand-ai-designed-gene-delivery-assets/>), European Biotechnology, 2026-10-06

---

The Bench wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://european-biotechnology.com/latest-news/rougetx-launches-with-58m-to-tackle-rare-bleeding-disorder/>
[2]: <https://www.genengnews.com/topics/drug-discovery/sensible-biotechnologies-raises-47m-to-expand-next-generation-platform-for-mrna-medicines/>
[3]: <https://european-biotechnology.com/latest-news/whitelab-secures-26m-to-expand-ai-designed-gene-delivery-assets/>